|
|
Neurobiogen Corporation is a bio-pharmaceutical company committed
to the discovery and development of new drugs to
treat diseases for which there is significant
unmet medical need. Neurobiogen pioneers an emerging area of
biotechnology known as regenerative
medicine. Neurobiogen's products are
designed to support the regeneration of
cells and tissue with its ability to repair
damage caused by disease, trauma or age. |
Innovative
therapies based on this knowledge can be used to
a broad range of unmet medical needs, including
those associated with neurological disorders
such as: traumatic
brain injury, stroke,Alzheimer's
disease, Parkinson's
disease, Edema,Multiple
Sclerosis , neuropathic
pain and brain
cancer.
|
|
Neurobiogen's
first drug candidate in clinical development
is NB-3108, a
neuroprotective and neurogenesis agent.
NB-3108 is a novelneuroprotective
agent for acute treatment of stroke and
traumatic brain injury (TBI), as well as for
prophylactic treatment of neurological
damage associated with coronary artery
bypass graft (CABG). |
The
initial targeted application of NB-3108
is for the treatment of stroke, which is
the third leading cause of death in the
US, Europe, and Japan. Over 500,000
stroke victims are reported every year
in the US alone. There are approximate
500,000 ischemic incidents resulting
from traumatic brain injury and open
heart surgery, such as coronary artery
bypass graft (CABG).
|
|
Driven
by its mission to develop drugs with superior
safety and efficacy, Neurobiogen uses
sophisticated methods of drug design in
combination with the MICROS Infusion System, an advanced drug delivery system to invent new and to
improve existing therapeutic compounds. Neuro
Biomed's proprietary technologies have resulted
in products that have increased efficacy and/or
reduced side effects relative to their
precursors and to competing products. |
| |
|
|
Neurobiogen applies a commercially driven approach to
R&D activities, while seeking to partner
with other pharmaceutical companies to generate
income, share risk and assist in the validation
of the underlying technologies.
For further
information, please feel free to contact us at info@neurobiogen.com | | |
|
